A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be ...

Starting with the Brestri Aerosphere COPD inhaler (pending regulatory approval), AstraZeneca intends to transition all of its MDIs to this technology by 2030. “The work we are doing with ...

Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...

AZ is also developing a rival triple therapy inhaler, Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), which is already approved in the US in COPD and is in late-stage ...

"Before, there was that balance of 'what is time worth?' And now, that's taken that stress away somewhat." ...